Controlled electronic carrier for somatic stem cells and Hemocomponentes for therapeutic use

• Grant number: 17/18065-2
• Support Opportunities: Research Grants - Innovative Research in Small Business - PIPE
• Start date: October 01, 2019
• End date: March 31, 2022
• Field of knowledge: Agronomical Sciences - Veterinary Medicine
• Principal Investigator: Osnir Yoshime Watanabe
• Grantee: Osnir Yoshime Watanabe
• Company: WTA - Watanabe Tecnologia Aplicada Ltda. - EPP
• CNAE: Fabricação de artefatos de material plástico não especificados anteriormente ; Fabricação de aparelhos e equipamentos de medida, teste e controle ; Fabricação de aparelhos eletromédicos e eletroterapêuticos e equipamentos de irradiação
• City: Cravinhos
• Pesquisadores principais: Robinson Antonio Martins de Oliveira ; yeda fumie watanabe
• Associated researchers: Angelo José Roncali da Silva ; Carlos Eduardo Ambrósio ; Dimas Tadeu Covas ; Fabiana Fernandes Bressan ; Felipe Perecin ; Flávio Vieira Meirelles ; Juliano Coelho da Silveira ; Maristela Delgado Orellana ; Simone Kashima Haddad
• Associated research grant: 14/22779-2 - Electronic controlled carrier for somatic stem cells for therapeutic use, AP.PIPE
• Associated scholarship(s): 19/22796-8 - Controlled electronic carrier for somatic stem cells and hemocomponentes for therapeutic use, BP.PIPE

Abstract

A cell carrier development, built with resistant material and equipped with an electronic refrigeration control system, will allow the transport of various cell types sensitive to degradation by temperature in order to preserve their biological properties. In Brazil the transport of blood components use PVC or styrofoam (EPS) boxes, having as refrigerant material, ice or thermal gel. Under these conditions the temperature of the material may vary from 2C to 24 Celsius degrees depending on the elapsed time in the transport and the environmental conditions (ANVISA 2nd ed.2016).Currently, stem cell research for therapeutic purposes is growing in both human medicine (Willeton et al., 2013, Ramsay et al., 2010, Weiss et al., 2006) and in veterinary medicine (BRETON et al., 2013). To ensure the maintenance of its therapeutic properties the transport of these cells must be done avoiding large temperature variations. Lightweight carriers for cell transport, with active cooling and up to 24 hours autonomy are not found on electronic sales sites. With the knowledge acquired in the design of the oocyte transporter (TO 16i® WTA), which includes high-precision temperature sensors, this project intends to offer a reliable technology product that meets the needs in question and with increasing potential of commercial exploitation in the medium and long term. To ensure commercial success, its development complies with ANVISA resolutions on the Health Regulations for the transport of human biological material (RDC 20/2014; Good Practice in the Blood Cycle (RDC 34/2014), Operation of Haematopoietic Progenitor Cell Laboratories ( RDC 56/2010) and Centers of Cellular Technology (RDC 9/2011).The WTA company has been active in the reproductive biotechnology market for more than a decade, with a high capacity for innovation, with several patents generated from its research and development (R & D) activities aimed at the logistics of biological material of animal origin. The tests carried out in phase 1, of performance verification with the first prototype of the carrier, demonstrated a high degree of reliability of the refrigerated chamber, thermal insulation and energy autonomy. Evaluations of the biological properties of human stem cells, carried out after 24-hour transport, demonstrated differential cell integrity at the 4C and 12 Celsius degrees tested temperatures. The product under development has the potential to meet the demand for transportation of various types of mammalian cells and tissues for therapeutic or non-therapeutic purposes and requiring strict temperature control. Transport services for services such as hemotherapy, clinical laboratories, hospitals, clinics, cell banks, tissue banks or the like, using our own or third-party transportation infrastructure will, in our view, be the first beneficiaries. Phase 2 is aimed at improving the equipment in terms of reducing its size, developing new attributes and continuing to test the viability of human cells for different periods of time. It also aims to include studies on the transport of stem cells from the veterinary segment and to develop the technology for the cultivation and evaluation of stem cells of the genus Equino. (AU)